...
首页> 外文期刊>Journal of Controlled Release: Official Journal of the Controlled Release Society >Detection of atherosclerotic lesions and intimal macrophages using CD36-targeted nanovesicles
【24h】

Detection of atherosclerotic lesions and intimal macrophages using CD36-targeted nanovesicles

机译:使用靶向CD36的纳米囊泡检测动脉粥样硬化病变和内膜巨噬细胞

获取原文
获取原文并翻译 | 示例
           

摘要

Current approaches to the diagnosis and therapy of atherosclerosis cannot target lesion-determinant cells in the artery wall. Intimal macrophage infiltration promotes atherosclerotic lesion development by facilitating the accumulation of oxidized low-density lipoproteins (oxLDL) and increasing inflammatory responses. The presence of these cells is positively associated with lesion progression, severity and destabilization. Hence, they are an important diagnostic and therapeutic target. The objective of this study was to noninvasively assess the distribution and accumulation of intimal macrophages using CD36-targeted nanovesicles. Soy phosphatidylcholine was used to synthesize liposome-like nanovesicles. 1-(Palmitoyl)-2-(5-keto-6-octene-dioyl) phosphatidylcholine was incorporated on their surface to target the CD36 receptor. All in vitro data demonstrate that these targeted nanovesicles had a high binding affinity for the oxLDL binding site of the CD36 receptor and participated in CD36-mediated recognition and uptake of nanovesicles by macrophages. Intravenous administration into LDL receptor null mice of targeted compared to non-targeted nanovesicles resulted in higher uptake in aortic lesions. The nanovesicles co-localized with macrophages and their CD36 receptors in aortic lesions. This molecular target approach may facilitate the in vivo noninvasive imaging of atherosclerotic lesions in terms of intimal macrophage accumulation and distribution and disclose lesion features related to inflammation and possibly vulnerability thereby facilitate early lesion detection and targeted delivery of therapeutic compounds to intimal macrophages. (C) 2015 Elsevier B.V. All rights reserved.
机译:当前诊断和治疗动脉粥样硬化的方法不能靶向动脉壁中的病变决定细胞。内膜巨噬细胞浸润通过促进氧化的低密度脂蛋白(oxLDL)的积累和增加炎症反应而促进动脉粥样硬化病变的发展。这些细胞的存在与病变的进展,严重程度和失稳呈正相关。因此,它们是重要的诊断和治疗目标。这项研究的目的是使用CD36靶向的纳米囊泡无创地评估内膜巨噬细胞的分布和积累。大豆磷脂酰胆碱用于合成脂质体样纳米囊泡。将1-(棕榈酰基)-2-(5-酮-6-辛烯-二酰基)磷脂酰胆碱掺入其表面以靶向CD36受体。所有体外数据表明,这些靶向的纳米囊泡对CD36受体的oxLDL结合位点具有很高的结合亲和力,并且参与了巨噬细胞对CD36介导的纳米囊泡的识别和摄取。与未靶向的纳米囊泡相比,对靶向LDL受体无效的小鼠静脉内给药导致主动脉病变的摄取更高。纳米囊泡与巨噬细胞及其CD36受体在主动脉病变共定位。这种分子靶向方法可以促进内膜巨噬细胞积累和分布方面的动脉粥样硬化病变的体内非侵入性成像,并揭示与炎症和可能的脆弱性有关的病变特征,从而促进早期病变的检测以及将治疗性化合物靶向递送至内膜巨噬细胞。 (C)2015 Elsevier B.V.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号